Literature DB >> 29242042

Neoadjuvant chemotherapy in breast cancer: more than just downsizing.

Marloes G M Derks1, Cornelis J H van de Velde2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29242042     DOI： 10.1016/S1470-2045(17)30914-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  23 in total

1.  Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.

Authors:  Ramon Colomer; Cristina Saura; Pedro Sánchez-Rovira; Tomás Pascual; Isabel T Rubio; Octavio Burgués; Lourdes Marcos; César A Rodríguez; Miguel Martín; Ana Lluch
Journal:  Oncologist       Date:  2019-02-01

2.  Chemotherapy-associated steatohepatitis was concomitant with epicardial adipose tissue volume increasing in breast cancer patients who received neoadjuvant chemotherapy.

Authors:  Xiaoxia Wang; Yuchuan Tan; Daihong Liu; Hesong Shen; Yongchun Deng; Yong Tan; Lei Wang; Yipeng Zhang; Xin Ma; Xiaohua Zeng; Jiuquan Zhang
Journal:  Eur Radiol       Date:  2022-04-08       Impact factor: 5.315

3.  Study protocol: Randomized, open-label, non-inferiority clinical trial for evaluating the clinical and pathological response rates to neoadjuvant hormone therapy and chemotherapy in patients with luminal-subtype breast tumors.

Authors:  Maria Carolina Gouveia; Candice Amorim de Araújo Lima Santos; Ariani Impieri Souza
Journal:  Contemp Clin Trials Commun       Date:  2022-10-08

4.  Contrast-free MRI quantitative parameters for early prediction of pathological response to neoadjuvant chemotherapy in breast cancer.

Authors:  Siyao Du; Si Gao; Ruimeng Zhao; Hongbo Liu; Yan Wang; Xixun Qi; Shu Li; Jibin Cao; Lina Zhang
Journal:  Eur Radiol       Date:  2022-03-10       Impact factor: 7.034

5.  Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.

Authors:  M J M Magbanua; L B Swigart; H-T Wu; G L Hirst; C Yau; D M Wolf; A Tin; R Salari; S Shchegrova; H Pawar; A L Delson; A DeMichele; M C Liu; A J Chien; D Tripathy; S Asare; C-H J Lin; P Billings; A Aleshin; H Sethi; M Louie; B Zimmermann; L J Esserman; L J van 't Veer
Journal:  Ann Oncol       Date:  2020-11-21       Impact factor: 51.769

6.  Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.

Authors:  Li Chen; Xiangyi Kong; Zhongzhao Wang; Xiangyu Wang; Yi Fang; Jing Wang
Journal:  J Cell Mol Med       Date:  2020-01-27       Impact factor: 5.310

7.  Kai-Xin-San Attenuates Doxorubicin-Induced Cognitive Impairment by Reducing Inflammation, Oxidative Stress, and Neural Degeneration in 4T1 Breast Cancer Mice.

Authors:  Wenjiao Lyu; Mingzi Ouyang; Xiaomeng Ma; Tiantian Han; Dajin Pi; Shijun Qiu
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-12       Impact factor: 2.629

Review 8.  Graphene-based nanomaterials for breast cancer treatment: promising therapeutic strategies.

Authors:  Guangman Cui; Junrong Wu; Jiaying Lin; Wenjing Liu; Peixian Chen; Meng Yu; Dan Zhou; Guangyu Yao
Journal:  J Nanobiotechnology       Date:  2021-07-15       Impact factor: 10.435

9.  Contrast-Enhanced Spectral Mammography-Based Radiomics Nomogram for the Prediction of Neoadjuvant Chemotherapy-Insensitive Breast Cancers.

Authors:  Zhongyi Wang; Fan Lin; Heng Ma; Yinghong Shi; Jianjun Dong; Ping Yang; Kun Zhang; Na Guo; Ran Zhang; Jingjing Cui; Shaofeng Duan; Ning Mao; Haizhu Xie
Journal:  Front Oncol       Date:  2021-02-22       Impact factor: 6.244

10.  Multiparametric MRI-based radiomics analysis for the prediction of breast tumor regression patterns after neoadjuvant chemotherapy.

Authors:  Xiaosheng Zhuang; Chi Chen; Zhenyu Liu; Liulu Zhang; Xuezhi Zhou; Minyi Cheng; Fei Ji; Teng Zhu; Chuqian Lei; Junsheng Zhang; Jingying Jiang; Jie Tian; Kun Wang
Journal:  Transl Oncol       Date:  2020-08-03       Impact factor: 4.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.